Evidence map›Paper›PMID 26496016›Full record

ArticleJournal of affective disorders2016

Establishing the cut-off score for remission and severity-ranges on the Psychotic Depression Assessment Scale (PDAS).

Søren D Østergaard, Anthony J Rothschild, Alastair J Flint, Benoit H Mulsant, Ellen M Whyte, Tom Vermeulen, Per Bech, Barnett S Meyers

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of affective disorders, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 3 countries.

Søren D ØstergaardDepartment of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark; Department P - Research, Aarhus University Hospital-Risskov, Risskov, Denmark. Electronic address: soeoes@rm.dk.
Anthony J RothschildUniversity of Massachusetts Medical School and University of Massachusetts Memorial Health Care, Worcester, MA, USA.
Alastair J FlintDepartment of Psychiatry, University Health Network, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
Benoit H MulsantDepartment of Psychiatry, University of Toronto, Toronto, Ontario, Canada; Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Western Psychiatric Institute and Clinic, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Ellen M WhyteWestern Psychiatric Institute and Clinic, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Tom VermeulenCollaborative Antwerp Psychiatric Research Institute, Psychiatric Hospital Duffel, Duffel, Belgium.
Per BechPsychiatric Research Unit, Psychiatric Center North Zealand, Copenhagen University Hospital, Hillerød, Denmark.
Barnett S MeyersDepartment of Psychiatry, Weill Medical College of Cornell University and New York Presbyterian Hospital, Westchester Division, White Plains, NY, USA.
Aarhus University Hospital · DKCentre for Addiction and Mental Health · CANew York Hospital Queens · USRegion Zealand · DKUniversity Health Network · CAUniversity of Massachusetts Chan Medical School · USUniversity of Pittsburgh · US

Funding

Disparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2M
UNIVERSITY OF PITTSBURGH CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE: BPCAUL1RR024153 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2006 to 2011
$73.9M
University of Pittsburgh Clinical and Translational Science InstituteUL1TR000005 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2012 to 2015
$50.8M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR024996 · NCRR · WEILL MEDICAL COLL OF CORNELL UNIV · PI IMPERATO-MCGINLEY, JULIANNE L · 2007 to 2011
$49.6M
WITHIN SUBJ VARIABILITY IN MEASUREMENTS DRUG METABOL ENZYMES IN HLTY SUBJM01RR000056 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEVINE, ARTHUR S · 1985 to 2006
$29.2M
Acute Pharmacotherapy of Psychotic DepressionU01MH062518 · NIMH · WEILL MEDICAL COLL OF CORNELL UNIV · PI ALEXOPOULOS, GEORGE S · 2002 to 2015
$5.0M
Acute Pharmacotherapy of Unipolar Psychotic DepressionU01MH062565 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WHYTE, ELLEN M · 2002 to 2015
$3.0M
Acute Pharmacotherapy of Unipolar Psychotic DepressionU01MH062624 · NIMH · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ROTHSCHILD, ANTHONY J · 2002 to 2015
$2.9M
Acute Pharmacotherapy of Unipolar Psychotic DepressionU01MH062446 · NIMH · UNIVERSITY HEALTH NETWORK · PI FLINT, ALASTAIR J. · 2002 to 2015
$2.0M
Intervention to Prevent Post-Stroke Major DepressionK23MH067710 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WHYTE, ELLEN M · 2004 to 2008
$857k
Complex Trials for Severe Geriatric Mood DisordersK24MH069430 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MULSANT, BENOIT H · 2004 to 2008
$601k
NCATS NIH HHS UL1 TR000005NCATS NIH HHS UL1 TR002384NCRR NIH HHS M01-RR024153NCRR NIH HHS RR000056NCRR NIH HHS UL1RR024996NIMH NIH HHS K23 MH067710NIMH NIH HHS MH067710NIMH NIH HHS MH069430NIMH NIH HHS MH 62446NIMH NIH HHS MH62518NIMH NIH HHS MH62565NIMH NIH HHS MH62624NIMH NIH HHS P30MH068368NIMH NIH HHS U01 MH062446NIMH NIH HHS U01 MH062518NIMH NIH HHS U01 MH062565NIMH NIH HHS U01 MH062624
6 · The paper itself

Abstract

backgroundThe Psychotic Depression Assessment Scale (PDAS) is a rating scale dedicated to the measurement of severity in psychotic depression (PD). The aim of this study was to establish the PDAS cut-off for remission of PD as well as PDAS score-ranges for mild, moderate, and severe PD. The secondary aim was to test how remission, as defined by the PDAS, would perform as outcome measure when applied to the data from a large randomized controlled trial (RCT) in PD.

methodsThe study was based on data from the Study of Pharmacotherapy in Psychotic Depression (STOP-PD). The cut-off for remission on the PDAS and the severity-ranges for mild, moderate, and severe PD were defined using the Clinical Global Impression - Severity scale (CGI-S) as reference by means of pair-wise receiver operating characteristic (ROC) analyses. Subsequently, it was tested whether remission on the PDAS could separate the effects of Olanzapine+Sertraline vs. Olanzapine+Placebo through an intention-to-treat, mixed-effects logistic regression of the data from STOP-PD.

resultsAccording to the ROC analyses, the ideal cut-off for remission of PD was a PDAS total score <8, while the severity-ranges for mild, moderate and severe PD were 8-15, 16-23, and >23 respectively. When applying the PDAS total score <8 (remission) as outcome on the STOP-PD data, treatment with Olanzapine+Sertraline performed significantly better than Olanzapine+Placebo (p<0.001). LIMITATIONS: The STOP-PD was not designed specifically to answer the research questions of the present study.

conclusionsAccording to this study, a total score <8 on the PDAS corresponds to remission of PD.

Indexed as

Psychiatric Status Rating ScalesRemission InductionSeverity of Illness IndexAntidepressive AgentsAntipsychotic AgentsBenzodiazepinesDrug Therapy, CombinationFemaleHumansMajor Depressive DisorderOlanzapineRandomized Controlled Trials as TopicROC CurveSertralineAntidepressive AgentsAntipsychotic AgentsBenzodiazepinesOlanzapineSertralineAffective disordersAntidepressive agentsAntipsychotic agentsPsychiatric status rating scalesPsychoticRemission induction

Identifiers

PMID26496016
PMCPMC4685000
OpenAlexW2138302999

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.